Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

Road 2025 to 2032 new year direction concept
Investing Articles

See the income from investing a £20k ISA in this UK stock before it goes ex-dividend on 9 April

Harvey Jones says this UK stock offers one of the highest yields on the FTSE 100. Investors need to act…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

What’s going on with the AstraZeneca share price now?

Dr James Fox explores the recent movements in the AstraZeneca share price and evaluates whether it's still a good long-term…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This S&P 500 stock is down 30% and the CEO just bought $10m worth of shares

Insiders only buy a stock for one reason – they expect its price to go up. So, this S&P 500…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

£5,000 invested in BAE Systems shares a month ago is now worth…

BAE Systems shares have been among the FTSE 100's best performers in recent years. The question is, can the defence…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

Here’s how a £20k ISA could generate £7,875 in monthly passive income

Have £20,000 ready to invest? Royston Wild explains how you could put this in a Stocks and Shares ISA to…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

By April 2027, £2,630 invested in Barclays shares could be worth…

Barclays shares have been flying. But what might happen to a chunk of money invested in the bank's stock over…

Read more »

Satellite on planet background
Investing Articles

MTI Wireless Edge: the 61p defence penny stock that’s delivered 10x the return of Rolls-Royce shares in 2026

Edward Sheldon has spotted a penny stock in the defence space that offers growth, value, dividend income, and share price…

Read more »

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing For Beginners

Is this the biggest bargain in the FTSE 100 right now?

Jon Smith reviews a FTSE 100 stock that's fallen by 18% so far this year that he believes could be…

Read more »